Clinical Evidence of Bee Venom Acupuncture for Ankle Pain: A Review of Clinical Research.

Ankle pain affects 9-15% of adults and accounts for nearly half of all sports injuries. When left untreated, ankle pain can lead to instability, repeat injuries, and chronic problems. Researchers reviewed 14 clinical studies to evaluate whether bee venom acupuncture (BVA) could safely and effectively treat ankle pain. Bee venom acupuncture involves injecting small amounts of purified bee venom into acupuncture points. The review included 9 case reports, 2 case-controlled trials, and 3 randomized controlled trials. Most ankle pain cases were caused by trauma (42.9%), followed by inflammatory conditions (21.4%) and nerve-related disorders (14.3%). Practitioners used bee venom concentrations between 0.05 and 0.5 mg/mL, with treatment volumes ranging from 0.04 to 2.5 mL per session. The majority of studies reported that BVA improved both ankle pain and function together. Side effects were generally mild when reported—only four patients across all studies experienced adverse reactions, all classified as mild to moderate (grade 1-2). These included minor local reactions like itching or swelling. The researchers concluded that BVA shows promise for managing ankle pain, though they noted important limitations: only three studies were high-quality randomized trials, and half the studies didn't report whether side effects occurred at all. This means more rigorous research is needed to fully understand BVA's safety and effectiveness for ankle pain. If you're considering bee venom acupuncture for ankle pain, seek treatment from a licensed acupuncturist with specialized training in bee venom therapy.

This systematic review evaluated bee venom acupuncture (BVA) for ankle pain management across 14 clinical studies (9 case reports, 2 CCTs, 3 RCTs) identified through searches of 10 databases through March 2025. Ankle pain etiologies included traumatic (42.9%), inflammatory (21.4%), and neuropathic (14.3%) conditions. BVA protocols utilized concentrations of 0.05-0.5 mg/mL with per-session volumes of 0.04-2.5 mL. Most studies reported concurrent improvements in pain and functional outcomes. Adverse events were documented in four participants across all studies, categorized as CTCAE grade 1-2 (mild to moderate severity). The review suggests BVA may offer therapeutic benefit for ankle pain; however, significant methodological limitations exist. Only three high-quality RCTs were identified, and 50% of included studies failed to report safety data. The authors conclude that while clinical evidence supports BVA consideration for ankle pain management, substantial gaps in high-quality evidence necessitate further rigorous clinical trials to establish definitive safety and efficacy profiles.